Market Overview

UPDATE: JP Morgan Initiates DaVita HealthCare Partners at Overweight on Growth Outlook

Share:
Related DVA
Worst Performing Industries For August 19, 2016
Earnings Scheduled For August 8, 2016
DaVita HealthCare: How Bad The Medicaid/Medicare RFI Really Is - And Why You Can Still Hold The Stock (Seeking Alpha)

JP Morgan initiated coverage on DaVita HealthCare Partners (NYSE: DVA) with an Overweight rating and a $125 price target.

JP Morgan said, "By combining the steady growth and cash generation of the company's core dialysis business with the best physician practice management asset in the country, HealthCare Partners (HCP), CEO Kent Thiry has positioned DVA at the forefront of a potentially long-term shift in healthcare delivery and reimbursement heading into reform implementation. The capability of properly incentivized, sophisticated primary care physicians to lower system costs is unquestioned, leaving only the pace and magnitude of opportunity to be decided going forward, with DVA perhaps best positioned of all to benefit."

DaVita HealthCare Partners closed at $110.87 on Wednesday.

Latest Ratings for DVA

DateFirmActionFromTo
Aug 2016JP MorganMaintainsNeutral
Mar 2016BernsteinMaintainsMarket Perform
Sep 2015JP MorganInitiates Coverage onNeutral

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (DVA)

View Comments and Join the Discussion!